{
  "coder": "Study coordinator (Claude Opus 5.5): every screened candidate page read and classified into prereg §4 E1 classes by its own article and date, never by page furniture added after citation; every text-route candidate read",
  "codedAt": "2026-10-11",
  "scope": "Cycles in the congress and after windows through 10 Oct 2026 (Saudi through 10 Oct). 11 Oct is added on 11 Oct.",
  "sources": [
    {
      "series": "saudi-t1d",
      "url": "https://diatribe.org/diabetes-research/top-diabetes-news-easd-2026",
      "class": "d-media",
      "readouts": [
        "EASD 2026 type 1 diabetes programme (agent set + teplizumab abstracts)",
        "TRIUMPH-2 (retatrutide)",
        "Other EASD 2026 data (not in the readout set)"
      ],
      "pageDate": "2026-10-05",
      "fetchedAt": "2026-10-11T08:40:00Z",
      "qualifying": "New insights on diabetes treatment, management, and technology emerged from the European Association for the Study of Diabetes (EASD) 2026 conference in Milan, Italy.",
      "note": "diaTribe, 5 Oct 2026: EASD 2026 round-up (continuous ketone monitoring with dapagliflozin in type 1; finerenone in type 1 with kidney disease; retatrutide in type 2 (TRIUMPH-2 data, trial not named); first real-world Tzield courses in the UK and Italy; survodutide; eloralintide with tirzepatide; and others). Read in a browser: the scripted fetch returned 403.",
      "readVia": "browser",
      "revisions": [
        {
          "revisedAt": "2026-10-11",
          "previousClass": "d-media",
          "previousReadouts": [
            "Other EASD 2026 data (not in the readout set)"
          ],
          "reason": "Full re-read of the article. Two of its items carry readouts without naming the trial, which the term screen cannot see. (1) \"Retatrutide Promotes Weight Loss in People With Type 2 Diabetes\": a late-stage trial of 1,152 people with type 2 diabetes and overweight or obesity over 80 weeks, nearly 19% weight loss at the highest dose and A1C -1.45%. These match the TRIUMPH-2 presentation of 30 Sep (1,152 adults, 80 weeks, 18.8% at 12 mg on the treatment-regimen estimand; Lilly's release gives 20.8% on the efficacy estimand). Class (d) turns on the article date (5 Oct) and its reporting congress data; a topline release before the congress does not change it. (2) \"Tzield Therapy Begins in European Countries\": first real-world teplizumab courses in stage 2 type 1 diabetes in the UK (10 people) and Italy (18 children), reported in the EASD 2026 round-up; teplizumab abstracts are in the Saudi programme readout (D10). The abstract number (373, 376 or 745) was not matched. The earlier entry recorded TRIUMPH-2 in its note but not in its readouts."
        }
      ],
      "readoutsUnverifiedAtCitation": [
        "TRIUMPH-2 (retatrutide)"
      ],
      "adjudication": "URL: https://diatribe.org/diabetes-research/top-diabetes-news-easd-2026, cited verbatim by Claude in one admitted Saudi answer (87f5a541a5, cycle SA-C17, 2026-10-08T16:31Z, a question asking for an evaluation of Tzield; question text withheld under protocol §10); cited in no UAE or Singapore answer. Registered eligibility: class (d), media dated 5 Oct (on or after 28 Sep) reporting congress data, so the answer counts as citing a congress-derived source. TRIUMPH-2: the article's retatrutide item satisfies the TRIUMPH-2 classification without naming the trial (same population, size, duration and effect as the 30 Sep presentation). Historical content: no archived copy; the article date precedes the answer by three days; the Tzield item is shown to have been present (the answer repeats it), the retatrutide item is not. Verdict: QUALIFYING SOURCE (class d) for the Saudi arm, labelled with the Saudi programme readout (teplizumab real-world item, verified at citation) and other EASD 2026 data. TRIUMPH-2 is UNVERIFIED AT CITATION: reported as unverified, not counted, and not treated as negative. It could never enter the registered TRIUMPH-2 cell, which belongs to the UAE series, where no answer cited this page: the registered UAE result stays \"not observed by day 11.3\".",
      "contentAtCitation": "Cited by Claude, exact URL (not a redirect), in Saudi answer 87f5a541a5 of cycle SA-C17, captured 2026-10-08T16:31Z, three days after the article date (5 Oct). No archived copy exists (Wayback Machine: no snapshot, checked 11 Oct). The Tzield item is corroborated: the answer repeats it (\"Real-world studies continue to provide evidence of its safety and efficacy as a therapy for slowing the progression of type 1 diabetes\"; \"temporary drops in white blood cell counts, rashes, and gastrointestinal issues\"). The retatrutide item is not corroborated: the answer does not use it, and today's page cannot show it was there on 8 Oct."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p1098",
      "class": "c-sponsor",
      "readouts": [
        "Other EASD 2026 data (not in the readout set)"
      ],
      "pageDate": "2026-10",
      "fetchedAt": "2026-10-10T16:56:15.805Z",
      "qualifying": "[quotation withheld: page cited only by Gemini]",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://sadanews.ps/en/news/339566.html",
      "class": "d-media",
      "readouts": [
        "Other EASD 2026 data (not in the readout set)"
      ],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:54:12.336Z",
      "qualifying": "The study's results, led by the University Medical Center in the German city of Ulm in collaboration with Boston Children's Hospital and Harvard Medical School in the United States, were presented on Friday at the annual meeting of the European Association for the Study of Diabetes, currently taking place in Milan, Italy.",
      "note": "Sada News: a diet study in children presented at EASD \"currently taking place\"; the page prints no date, so its date rests on that wording (Friday 2 Oct 2026)."
    },
    {
      "series": "uae-glp1",
      "url": "https://biopharmadive.com/news/3-takeaways-from-european-obesity-scientific-meeting/831870",
      "class": "d-media",
      "readouts": [
        "OCTANE (switch to oral semaglutide, real-world), LBA 59",
        "Other EASD 2026 data (not in the readout set)"
      ],
      "pageDate": "2026-10-01",
      "fetchedAt": "2026-10-10T17:25:56.005Z",
      "qualifying": "At EASD, it presented data from a “real world” study of de-identified patient data it did in conjunction with direct-to-consumer partner Ro.",
      "note": "BioPharma Dive, 1 Oct 2026: EASD 2026 round-up reporting OCTANE (4.1% after switching to the Wegovy pill) and other congress data (eloralintide with tirzepatide, survodutide, ABBV-295). Readable only on the browser-header retry. Re-read in full 11 Oct: retatrutide appears only as data that \"impressed investors in May\" (before the congress); no other readout-set result is reported."
    },
    {
      "series": "uae-glp1",
      "url": "https://biospace.com/press-releases/lillys-zepbound-tirzepatide-10-mg-and-15-mg-was-associated-with-more-weight-loss-than-wegovy-hd-semaglutide-injection-7-2-mg-in-a-new-indirect-treatment-comparison",
      "class": "c-sponsor",
      "readouts": [
        "Other EASD 2026 data (not in the readout set)"
      ],
      "pageDate": "2026-09-29",
      "fetchedAt": "2026-10-10T16:33:42.573Z",
      "qualifying": "1,2,3 These results, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, add to the growing body of evidence comparing Zepbound and Wegovy, including SURMOUNT-5, a randomized controlled Phase 3b trial in which Zepbound 10 mg and 15 mg demonstrated superior weight loss compared with Wegovy 1.7 mg and 2.4 mg.",
      "note": "Lilly release, 29 Sep 2026: indirect comparison of tirzepatide with semaglutide 7.2 mg presented at EASD 2026."
    },
    {
      "series": "uae-glp1",
      "url": "https://biospace.com/press-releases/people-switching-from-weight-loss-injections-to-novos-wegovy-pill-lost-4-1-body-weight-on-average-after-three-months-according-to-real-world-data-presented-at-easd2026",
      "class": "c-sponsor",
      "readouts": [
        "OCTANE (switch to oral semaglutide, real-world), LBA 59"
      ],
      "pageDate": "2026-09-30",
      "fetchedAt": "2026-10-10T16:33:44.952Z",
      "qualifying": "1 OCTANE was presented during a short oral session at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, on September 30, 2026.",
      "note": "Novo release, 30 Sep 2026: OCTANE, LBA 59."
    },
    {
      "series": "uae-glp1",
      "url": "https://cnbc.com/2026/09/30/eli-lilly-obesity-drug-amylin-tirzepatide-weight-loss-trial.html",
      "class": "d-media",
      "readouts": [
        "Other EASD 2026 data (not in the readout set)"
      ],
      "pageDate": "2026-09-30",
      "fetchedAt": "2026-10-10T16:33:54.071Z",
      "qualifying": "A potential winning approach Results were presented at the European Association for the Study of Diabetes in Milan, Italy.",
      "note": "CNBC, 30 Sep 2026: eloralintide with tirzepatide, phase 2, presented at EASD 2026."
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p0348",
      "class": "d-media",
      "readouts": [
        "Other EASD 2026 data (not in the readout set)"
      ],
      "pageDate": "2026-10",
      "fetchedAt": "2026-10-10T16:44:48.089Z",
      "qualifying": "[quotation withheld: page cited only by Gemini]",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p0770",
      "class": "d-media",
      "readouts": [
        "OCTANE (switch to oral semaglutide, real-world), LBA 59"
      ],
      "pageDate": "2026-10",
      "fetchedAt": "2026-10-10T16:44:48.044Z",
      "qualifying": "[quotation withheld: page cited only by Gemini]",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p0917",
      "class": "d-media",
      "readouts": [
        "OCTANE (switch to oral semaglutide, real-world), LBA 59"
      ],
      "pageDate": "2026-09",
      "fetchedAt": "2026-10-10T16:44:48.021Z",
      "qualifying": "[quotation withheld: page cited only by Gemini]",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0675",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:54:20.459Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://bestpractice.bmj.com/topics/en-us/25",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:55:08.926Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://bestpractice.bmj.com/topics/en-us/25?locale=it",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:51:11.004Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://bestpractice.bmj.com/topics/en-us/25?locale=tr",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:54:44.823Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://biomedres.us/[path-withheld-001]",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2019-09",
      "fetchedAt": "2026-10-10T16:54:42.383Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://biospace.com/fda/eli-lillys-weekly-insulin-shot-cleared-by-fda-setting-up-another-front-in-novo-rivalry",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-09-24",
      "fetchedAt": "2026-10-10T16:55:00.493Z",
      "qualifying": "",
      "note": "Article dated 24 Sep 2026 on an FDA approval; refers to data presented at EASD 2024."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0143",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-12",
      "fetchedAt": "2026-10-10T16:56:23.467Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://businesswire.com/news/home/20260928831177/en/Tandem-Mobi-Automated-Insulin-Delivery-System-Now-Available-in-Twelve-International-Markets",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-09-28",
      "fetchedAt": "2026-10-11T08:40:00Z",
      "qualifying": "",
      "note": "Tandem release, 28 Sep 2026, datelined Milan: product availability in 12 countries and an invitation to its EASD booth; reports no congress data. Read in a browser.",
      "readVia": "browser"
    },
    {
      "series": "saudi-t1d",
      "url": "[market-research-publisher-01]/p001",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:59:21.195Z",
      "qualifying": "",
      "note": "Disease and trials directory; agent names appear without congress data or date."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0155",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2023-12",
      "fetchedAt": "2026-10-10T16:56:21.747Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0271",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-10",
      "fetchedAt": "2026-10-10T16:56:48.702Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://cureus.com/articles/394021-the-impact-of-insulin-pump-therapy-on-glycemic-control-and-acute-diabetes-complications-in-type-1-diabetes-real-world-evidence-from-a-single-center",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-11T08:40:00Z",
      "qualifying": "",
      "note": "Journal article on insulin pump therapy; no EASD 2026 content. Read in a browser.",
      "readVia": "browser"
    },
    {
      "series": "saudi-t1d",
      "url": "https://diabetes.org/newsroom/international-experts-outline-diabetes-remission-diagnosis-criteria",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:56:33.929Z",
      "qualifying": "",
      "note": "Mentions EASD without reporting EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "[commercial-or-unclassified-site-099]/p001",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:59:17.286Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0431",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-10",
      "fetchedAt": "2026-10-11T16:38:58.526Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0208",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2013-08",
      "fetchedAt": "2026-10-10T16:54:53.818Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://diabetesonthenet.com/diabetes-primary-care/hba1c-practicalities-pitfalls",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-07-09",
      "fetchedAt": "2026-10-11T16:39:09.849Z",
      "qualifying": "",
      "note": "EASD 2026 text appears only in news or related-article items on the page as fetched 2026-10-11; the article itself (dated 2025-07-09) reports no congress data."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p1514",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "1998-12",
      "fetchedAt": "2026-10-10T16:59:31.581Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0796",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2020-09",
      "fetchedAt": "2026-10-10T16:56:46.438Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p1500",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:57:35.518Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[commercial-or-unclassified-site-125]/p001",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:56:29.115Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2025.1596188/full",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-07-01",
      "fetchedAt": "2026-10-10T16:51:05.848Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0806",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2022-06",
      "fetchedAt": "2026-10-10T16:55:45.317Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0225",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2023-05",
      "fetchedAt": "2026-10-10T16:55:45.176Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p1387",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:57:54.900Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://goodrx.com/tzield/what-is",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-11T08:40:00Z",
      "qualifying": "",
      "note": "Drug information page; no congress content. Read in a browser.",
      "readVia": "browser"
    },
    {
      "series": "saudi-t1d",
      "url": "https://hcplive.com/shorts/exciting-new-therapy-for-type-1-diabetes-management",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-10-10",
      "fetchedAt": "2026-10-10T16:55:24.708Z",
      "qualifying": "",
      "note": "EASD 2026 text appears only in news or related-article items on the page as fetched 2026-10-10; the article itself (dated 2026-10-10) reports no congress data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://hcplive.com/view/insulin-efsitora-alfa-onswik-gains-fda-approval-for-type-2-diabetes",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-09-24",
      "fetchedAt": "2026-10-10T16:54:57.185Z",
      "qualifying": "",
      "note": "EASD 2026 text appears only in news or related-article items on the page as fetched 2026-10-10; the article itself (dated 2026-09-24) reports no congress data."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p1051",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:57:18.566Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p1546",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2024-04",
      "fetchedAt": "2026-10-11T16:39:00Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]",
      "readVia": "browser"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0437",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2024-11",
      "fetchedAt": "2026-10-10T16:53:17.394Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://menafn.com/1111713343/Diabetes-Market-Growth-Outlook-2036-Epidemiology-Pipeline-Therapies-And-Revenue-Forecast-Delveinsight-Eli-Lilly-And-Company-Regor-Pharma-Astrazeneca-Eccogene-Pfizer-Sciwind-Biosciences",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-09-24",
      "fetchedAt": "2026-10-10T16:59:20.263Z",
      "qualifying": "",
      "note": "Market report dated 24 Sep 2026; agent names appear in a pipeline list, not congress data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://merckmanuals.com/professional/endocrine-and-metabolic-disorders/diabetes-mellitus-and-hypoglycemia/type-1-diabetes-mellitus?autoredirectid=36220&qt=diabetes",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-12-01",
      "fetchedAt": "2026-10-10T16:57:51.678Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://msdmanuals.com/professional/endocrine-and-metabolic-disorders/diabetes-mellitus-and-hypoglycemia/type-1-diabetes-mellitus?ruleredirectid=744autoredirectid%3D36220",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-12-01",
      "fetchedAt": "2026-10-10T16:55:31.991Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://ncbi.nlm.nih.gov/pmc/articles/PMC2327220",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:52:05.339Z",
      "qualifying": "",
      "note": "Refers to an earlier EASD meeting, not EASD 2026."
    },
    {
      "series": "saudi-t1d",
      "url": "https://ncbi.nlm.nih.gov/pmc/articles/PMC8879080",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:56:33.106Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://ncbi.nlm.nih.gov/sites/books/NBK568751",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2024-10-05",
      "fetchedAt": "2026-10-10T16:55:19.015Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p1004",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2015-05",
      "fetchedAt": "2026-10-10T16:57:43.679Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p1554",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2020-07",
      "fetchedAt": "2026-10-10T16:51:28.994Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[commercial-or-unclassified-site-196]/p001",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2021-03-11",
      "fetchedAt": "2026-10-10T16:52:08.495Z",
      "qualifying": "",
      "note": "Mentions EASD without reporting EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0186",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:59:31.318Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11442716",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:55:47.448Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11609227",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:55:33.050Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0742",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:57:07.248Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12259510",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:57:14.366Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12905110",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:57:14.667Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13435675",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:57:53.145Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2936120",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:55:59.378Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p1415",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:57:41.613Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5321245",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:56:31.051Z",
      "qualifying": "",
      "note": "2015 scientific statement on staging; a readout term matched incidentally."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0079",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-11T16:38:59.467Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0864",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:54:29.824Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9810477",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:57:06.535Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "https://reference.medscape.com/cc2/p10/management-type-1-diabetes-ada-easd-guidelines-2026a10010oy",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-11T16:39:24.389Z",
      "qualifying": "",
      "note": "Medscape guideline summary of the 2026 ADA/EASD consensus on type 1 diabetes in adults: a guideline, not a readout or trial result, so it is classed with the other consensus and guideline citations (§4 classes cover congress data, not society guidance)."
    },
    {
      "series": "saudi-t1d",
      "url": "https://sciencedaily.com/releases/2017/02/170216105523.htm",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:51:56.624Z",
      "qualifying": "",
      "note": "Press item from 2017; a readout term matched incidentally."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0594",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:53:38.453Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0767",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:55:13.789Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://thedailystar.net/health/diabetes-children-1203241",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:51:49.243Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0715",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-10",
      "fetchedAt": "2026-10-10T16:53:25.454Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "https://type1strong.org/blog-post/top-type-1-diabetes-research-breakthroughs-to-watch-in-2025",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-09-23",
      "fetchedAt": "2026-10-10T16:53:53.979Z",
      "qualifying": "",
      "note": "Reports the 2025 EASD meeting (Ver-A-T1D), not EASD 2026."
    },
    {
      "series": "saudi-t1d",
      "url": "https://tzield.com/?_ga=2.235561092.400369729.1707331657-617152617.1691160862",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-11T08:40:00Z",
      "qualifying": "",
      "note": "Brand home page; no congress content. Read in a browser.",
      "readVia": "browser"
    },
    {
      "series": "saudi-t1d",
      "url": "https://tzield.com/stage-2-t1d/patient-stories",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-11T08:40:00Z",
      "qualifying": "",
      "note": "Brand patient-stories page; no congress content. Read in a browser.",
      "readVia": "browser"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p0933",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-11T08:40:00Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]",
      "readVia": "browser"
    },
    {
      "series": "saudi-t1d",
      "url": "[gemini-only]/p1545",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-09",
      "fetchedAt": "2026-10-10T16:51:18.994Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "saudi-t1d",
      "url": "[platform-page:youtube.com]/p042",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:57:38.497Z",
      "qualifying": "",
      "note": "A readout term (SMARTEST (SGLT2 vs metformin first line)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "singapore-sglt2",
      "url": "https://aetna.com/products/rxnonmedicare/data/2025%20commercial/Antidiabetic_Agents_ST,_Post_PA_Policy_676-D,_BOG_6332-D_UDR_05-2024.html",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:50:52.581Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "singapore-sglt2",
      "url": "[gemini-only]/p0307",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2019-11",
      "fetchedAt": "2026-10-10T16:50:39.120Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "singapore-sglt2",
      "url": "[gemini-only]/p1203",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T17:30:18.812Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "singapore-sglt2",
      "url": "[gemini-only]/p0016",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T17:30:28.662Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "singapore-sglt2",
      "url": "[gemini-only]/p0404",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2014-07",
      "fetchedAt": "2026-10-10T16:49:49.606Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "singapore-sglt2",
      "url": "[care-provider-05]/p001",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-08-17",
      "fetchedAt": "2026-10-10T16:50:40.279Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "singapore-sglt2",
      "url": "[gemini-only]/p1399",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2016-06",
      "fetchedAt": "2026-10-10T16:50:42.402Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "singapore-sglt2",
      "url": "https://marketintelo.com/report/sglt2-inhibitors-market",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-08-25",
      "fetchedAt": "2026-10-10T16:50:34.002Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "singapore-sglt2",
      "url": "[gemini-only]/p0791",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2019-05",
      "fetchedAt": "2026-10-10T16:50:26.096Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "singapore-sglt2",
      "url": "https://pharmaphorum.com/news/fda-approves-jardiance-empagliflozin-for-wider-range-of-patients-with-heart-failure",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2022-02-25",
      "fetchedAt": "2026-10-10T16:49:53.589Z",
      "qualifying": "",
      "note": "Pharmaphorum article dated before 2026; \"New diabetes and obesity studies making waves at EASD\" is a related-news item on the page as fetched on 10 Oct, not the article."
    },
    {
      "series": "singapore-sglt2",
      "url": "https://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-in-chronic-kidney-disease",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2020-03-13",
      "fetchedAt": "2026-10-10T16:49:51.761Z",
      "qualifying": "",
      "note": "Pharmaphorum article dated before 2026; \"New diabetes and obesity studies making waves at EASD\" is a related-news item on the page as fetched on 10 Oct, not the article."
    },
    {
      "series": "singapore-sglt2",
      "url": "https://pharmaphorum.com/news/lilly-and-boehringer-rejig-diabetes-alliance-as-jardiance-soars",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2019-11-05",
      "fetchedAt": "2026-10-10T16:49:51.828Z",
      "qualifying": "",
      "note": "Pharmaphorum article dated before 2026; \"New diabetes and obesity studies making waves at EASD\" is a related-news item on the page as fetched on 10 Oct, not the article."
    },
    {
      "series": "singapore-sglt2",
      "url": "https://pharmaphorum.com/news/us-panel-narrowly-backs-heart-benefit-bililly-diabetes-drug",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2016-06-29",
      "fetchedAt": "2026-10-10T16:50:23.181Z",
      "qualifying": "",
      "note": "Pharmaphorum article dated before 2026; \"New diabetes and obesity studies making waves at EASD\" is a related-news item on the page as fetched on 10 Oct, not the article."
    },
    {
      "series": "singapore-sglt2",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10783160",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:50:05.168Z",
      "qualifying": "",
      "note": "A readout term (OCTANE (semaglutide 7.2 mg)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "singapore-sglt2",
      "url": "[gemini-only]/p0133",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:50:13.094Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "singapore-sglt2",
      "url": "[gemini-only]/p0834",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-11T14:32:14.611Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "singapore-sglt2",
      "url": "https://straitsresearch.com/report/sglt2-inhibitors-market",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:49:43.491Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p0827",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2014-10",
      "fetchedAt": "2026-10-10T16:44:53.073Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "uae-glp1",
      "url": "[local-fitness-business-83]/p001",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-06-10",
      "fetchedAt": "2026-10-10T16:30:52.417Z",
      "qualifying": "",
      "note": "A readout term (OCTANE (semaglutide 7.2 mg)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "[local-directory-or-listing-12]/p001",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-03-24",
      "fetchedAt": "2026-10-10T16:33:31.029Z",
      "qualifying": "",
      "note": "A readout term (SMARTEST (SGLT2 vs metformin first line)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "[local-nutrition-or-supplement-business-020]/p004",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-10-06",
      "fetchedAt": "2026-10-10T16:30:39.241Z",
      "qualifying": "",
      "note": "A readout term (SMARTEST (SGLT2 vs metformin first line)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "[local-nutrition-or-supplement-business-020]/p007",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-10-06",
      "fetchedAt": "2026-10-10T16:44:53.975Z",
      "qualifying": "",
      "note": "A readout term (SMARTEST (SGLT2 vs metformin first line)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "https://biospace.com/press-releases/novo-to-share-real-world-and-clinical-data-including-wegovy-pill-and-cardiometabolic-pipeline-progress-with-next-generation-amylin-treatments-at-easd-2026",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-09-16",
      "fetchedAt": "2026-10-10T16:30:59.646Z",
      "qualifying": "",
      "note": "Novo release dated 16 Sep 2026 announcing presentations at EASD 2026; dated before 28 Sep and reports no congress result, so it is not class (c)."
    },
    {
      "series": "uae-glp1",
      "url": "[local-retailer-or-delivery-23]/p015",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T17:27:57.904Z",
      "qualifying": "",
      "note": "A readout term (OCTANE (switch to oral semaglutide, real-world), LBA 59) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "[local-clinic-or-hospital-033]/p003",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2024-02-09",
      "fetchedAt": "2026-10-10T16:33:22.086Z",
      "qualifying": "",
      "note": "Mentions EASD without reporting EASD 2026 data."
    },
    {
      "series": "uae-glp1",
      "url": "[local-clinic-or-hospital-045]/p001",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2022-02-15",
      "fetchedAt": "2026-10-10T16:48:00.096Z",
      "qualifying": "",
      "note": "A readout term (SMARTEST (SGLT2 vs metformin first line)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p1216",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-06",
      "fetchedAt": "2026-10-10T16:44:17.984Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "uae-glp1",
      "url": "https://en.aletihad.ae/news/uae/4648855/world-obesity-day--how-abu-dhabi-is-winning-the-fight-agains",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-03-03",
      "fetchedAt": "2026-10-10T16:35:35.904Z",
      "qualifying": "",
      "note": "EASD 2026 text appears only in news or related-article items on the page as fetched 2026-10-10; the article itself (dated 2026-03-03) reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "[local-clinic-or-hospital-029]/p011",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-08-24",
      "fetchedAt": "2026-10-10T16:32:33.652Z",
      "qualifying": "",
      "note": "Cites an ADA/EASD consensus, position statement or guideline, or the EASD journal; reports no EASD 2026 data."
    },
    {
      "series": "uae-glp1",
      "url": "[local-directory-or-listing-11]/p001",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2024-04-26",
      "fetchedAt": "2026-10-11T14:25:46.436Z",
      "qualifying": "",
      "note": "A readout term (SMARTEST (SGLT2 vs metformin first line)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "[local-directory-or-listing-11]/p002",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-07-03",
      "fetchedAt": "2026-10-10T16:44:30.305Z",
      "qualifying": "",
      "note": "A readout term (SMARTEST (SGLT2 vs metformin first line)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "https://healthmagazine.ae/press_release/wegovy-pill-early-favourite-uae-fast-growing-oral-market",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-10-06",
      "fetchedAt": "2026-10-10T16:44:54.784Z",
      "qualifying": "",
      "note": "Sponsor-content article dated 6 Oct 2026 citing an \"ORION analysis\" (not in the EASD 2026 programme) and ACHIEVE-3 as a Lancet publication; reports no EASD 2026 data."
    },
    {
      "series": "uae-glp1",
      "url": "https://investorshub.advfn.com/market-news/article/29632/novo-nordisk-expands-wegovy-rollout-with-launch-of-weight-loss-pill-in-uae-nvo",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-06-03",
      "fetchedAt": "2026-10-10T16:33:44.102Z",
      "qualifying": "",
      "note": "Article dated 3 Jun 2026 (UAE launch of the Wegovy pill); the EASD sentences sit in news items on the page as fetched on 10 Oct, not in the article."
    },
    {
      "series": "uae-glp1",
      "url": "https://noom.com/blog/myfitnesspal-vs-loseit-vs-noom",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2022-05-09",
      "fetchedAt": "2026-10-10T16:30:59.633Z",
      "qualifying": "",
      "note": "A readout term (SMARTEST (SGLT2 vs metformin first line)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p0957",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-06",
      "fetchedAt": "2026-10-11T14:25:45.358Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p0929",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-05",
      "fetchedAt": "2026-10-10T16:33:53.128Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p0275",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-06",
      "fetchedAt": "2026-10-10T16:43:48.587Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "uae-glp1",
      "url": "https://noom.com/blog/weight-management/wegovy-vs-saxenda",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2025-04-01",
      "fetchedAt": "2026-10-10T16:45:09.949Z",
      "qualifying": "",
      "note": "A readout term (SMARTEST (SGLT2 vs metformin first line)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "https://noom.com/blog/weight-management/wegovy-vs-zepbound",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-02-11",
      "fetchedAt": "2026-10-10T16:45:10.056Z",
      "qualifying": "",
      "note": "A readout term (SMARTEST (SGLT2 vs metformin first line)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p1335",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:45:17.733Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "uae-glp1",
      "url": "https://nourish.com/blog/saxenda-vs-wegovy",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:31:17.335Z",
      "qualifying": "",
      "note": "A readout term (ACHIEVE programme (orforglipron)) matched incidentally (e.g. the word 'smartest', 'octane' or 'achieve' in ordinary text); the page reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "https://patientcareonline.com/view/early-intervention-in-weight-management-treating-pre-obesity",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2021-04-29",
      "fetchedAt": "2026-10-10T16:44:01.074Z",
      "qualifying": "",
      "note": "EASD 2026 text appears only in news or related-article items on the page as fetched 2026-10-10; the article itself (dated 2021-04-29) reports no congress data."
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p0500",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2017-06",
      "fetchedAt": "2026-10-10T16:46:00.527Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "uae-glp1",
      "url": "https://pharmaphorum.com/news/uk-mhra-authorises-orforglipron-private-prescription",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-08-24",
      "fetchedAt": "2026-10-10T16:33:06.911Z",
      "qualifying": "",
      "note": "Pharmaphorum article dated before 2026; \"New diabetes and obesity studies making waves at EASD\" is a related-news item on the page as fetched on 10 Oct, not the article."
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p1371",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:47:20.930Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "uae-glp1",
      "url": "[gemini-only]/p0367",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": null,
      "fetchedAt": "2026-10-10T16:35:13.196Z",
      "qualifying": "",
      "note": "[note withheld: page cited only by Gemini]"
    },
    {
      "series": "uae-glp1",
      "url": "https://us.headtopics.com/news/weight-loss-journey-from-prescription-drugs-to-a-natural-88309588",
      "class": "not-congress-derived",
      "readouts": [],
      "pageDate": "2026-09-30",
      "fetchedAt": "2026-10-10T16:35:23.186Z",
      "qualifying": "",
      "note": "Consumer story; the EASD sentence is a \"Read more\" item on the page as fetched, not the article."
    }
  ],
  "text": [
    {
      "sha256": "fe4020ace5419366ffa86004be91c15cc91b72bfd52218ff3c8ac60e92378fbc",
      "qualifies": false,
      "readouts": [],
      "span": "[answer text withheld under the Gemini constraints; engine not recorded]",
      "spanSha256": "9e56fe49ab6f7a45bc89fcc3cfcf228a46f06b215d325ed95dd0f965990a644c",
      "note": "Cites the 2021 ADA/EASD consensus on follow-up visits; reports no congress result."
    },
    {
      "sha256": "280e209ba8879a9c844c8de98b2721c88c6309a02984eda0ccfbb024b7073561",
      "qualifies": false,
      "readouts": [],
      "span": "In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the strongest Foundayo dose.",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "eb8f6d48ef2b559c0384137b4aa57262a48a43cf07ae11cc0d6706fb6c8c7272",
      "qualifies": false,
      "readouts": [],
      "span": "Injectable GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6% compared to Foundayo's 12.4%",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "a995a6b6824e82a5e2aa00f2225b49e740135531ca538257e1f8f26656ee218d",
      "qualifies": false,
      "readouts": [],
      "span": "In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the strongest Foundayo dose",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "fcfc3975f4c34077572d1a4c41a41546f051d287a21160005f229ea7df6eac80",
      "qualifies": false,
      "readouts": [],
      "span": "[Gemini answer text withheld]",
      "spanSha256": "c4f8281744d99d8a9e053faa464a64fdc23bfea8b53253dbf3d06e9f07314bc7",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "f17f49da88ccb18324cacf3c15abf38bea85fd63fa7bd9e67847697770cb8142",
      "qualifies": false,
      "readouts": [],
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2fd9a3fea73ceaef5133e025dfe1ee20670ffd92d0fcdecd81c9bb03d7c750e5",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "80bd447cd0cde6b139e87727da0d8d40e78a4eca344d395fe67ef48a32ff24b3",
      "qualifies": false,
      "readouts": [],
      "span": "Foundayo is a small-molecule (non-peptide) GLP-1 receptor agonist, taken once a day with or without food and at any time of day, with average weight loss at the highest dose around 12%, with some patients losing up to 15%.",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "b03f2796f981bbe1249c134d8509b26f3dc97b5e1fc69977150dbfff34319472",
      "qualifies": false,
      "readouts": [],
      "span": "People taking orforglipron lost an average of about 12% of their body weight over roughly 72 weeks, and head-to-head studies suggest it may outperform standard oral semaglutide tablets (Rybelsus) in both weight loss and blood sugar control.",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "e365d131327271a5c9b6b9fa06f79fc75bbb421884f1198e6367551d2a7da26c",
      "qualifies": false,
      "readouts": [],
      "span": "The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the strongest Foundayo dose",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "2145f3dc5504da72c1888442d23dbbf715eb3a59cf234ddf31e6a60169094eb3",
      "qualifies": false,
      "readouts": [],
      "span": "[answer text withheld under the Gemini constraints; engine not recorded]",
      "spanSha256": "b74a4c476f5bd054f9c617c21f906cfd530cc28aba2a937e32c821c671c6812a",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "217cb51565ae054c4634b99bac81abd67e3e5847e2d8f36b73cdd3362ff646f2",
      "qualifies": false,
      "readouts": [],
      "span": "[answer text withheld under the Gemini constraints; engine not recorded]",
      "spanSha256": "ec37badfc497c9cc7ceb5d681d1cf14a9de7d2103008760e4b8be81b6b2efcf2",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "c00d4a9cce45563832495f7d0e8b7ecdb0aa2fd68f51b4860d69101e9754ca3c",
      "qualifies": false,
      "readouts": [],
      "span": "[answer text withheld under the Gemini constraints; engine not recorded]",
      "spanSha256": "339a42e782cbda74ddf029747f4f061365b18bff3bd24414b9c352357528d681",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "2efbb304a1b73b0a1ebdaaadd557e33ab3e9b10c897f6ff1b307da0b0921bc41",
      "qualifies": false,
      "readouts": [],
      "span": "[answer text withheld under the Gemini constraints; engine not recorded]",
      "spanSha256": "2ecd08f8a628ffc09ba88b5de251a287c152d78ca65ff244554af6efbc041f50",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "99956b91f0e6b14d112924456e530761c791d73a5eb4e728326b2e292890d78b",
      "qualifies": false,
      "readouts": [],
      "span": "People taking orforglipron lost an average of about 12% of their body weight over roughly 72 weeks, and head-to-head studies suggest it may outperform standard oral semaglutide tablets (Rybelsus) in both weight loss and blood sugar control",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "08be24e0d7c28f2a63207e44560f03c86b05fc79f45cd845bbba43f961da5f7c",
      "qualifies": false,
      "readouts": [],
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f059b10b1a07ffe528cc627d57396540a9a853c9eb17e54cf45ec90d7cac1d66",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "38bbe8a645fe20642842c66a41a30fcb61db3d88cd1c0748bd9dacd9e3716d67",
      "qualifies": false,
      "readouts": [],
      "span": "Injectable GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6% compared to Foundayo's 12.4%",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "8b05957c60f49b4665630230037de51b4d9bd37796b30b9271ddf4fefa8d2dff",
      "qualifies": false,
      "readouts": [],
      "span": "**Recommendation:** For UAE consumers, **Foundayo** offers the best balance of convenience (daily pill, no needles, widely available through [local-pharmacy-30]), while **Mounjaro** provides the strongest weight loss results if you're willing to ",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "6da28f3fd48642b6e58b34837e0396045f818f645899aa143d72ab5ed423ea8d",
      "qualifies": false,
      "readouts": [],
      "span": "Clinical trials of orforglipron demonstrated promising results, including significant weight reduction when used alongside lifestyle modification guidance.",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "e8c801841c8644867f4f386b8d5c974fd058564470dc04574c89ef7779eacf74",
      "qualifies": false,
      "readouts": [],
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ba5076077d30feda856f31b5f83c7e6533c316ff4005c8fd8005bd50ae123c9c",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "ed9495e0ef79a465466d2ed2edff18d131bd9f8722347044af88a5f980a56f36",
      "qualifies": false,
      "readouts": [],
      "span": "People taking orforglipron lost an average of about 12% of their body weight over roughly 72 weeks, and head-to-head studies suggest it may outperform standard oral semaglutide tablets (Rybelsus) in both weight loss and blood sugar control.",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "7c6d5179fc772a023956986ebaf1677f209f3826b591d271c953c55698f30a1c",
      "qualifies": false,
      "readouts": [],
      "span": "| **Foundayo (orforglipron)** | Potentially attractive if genuinely registered and stocked locally | Around 12% in reported trial data[2][5] | Daily oral tablet; avoids injections | Newer product with less long-term real-world experience; v",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "cbbfaf358ee28d637087031a312a970ebbb5e15079f4c37126550b133863b88a",
      "qualifies": false,
      "readouts": [],
      "span": "Retatrutide remains in the clinical trial stage and has not been approved for use or distribution in the UAE",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "65ca9af90484495941532e3b4c2bff349c8f7481f4f301058631f4da113ef220",
      "qualifies": false,
      "readouts": [],
      "span": "[Gemini answer text withheld]",
      "spanSha256": "87c947da44b9807948c7f3cb093e996325d1a44ea430abfce33e29374d732a97",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "fb94cc2bbee9f7649a84b0f2267201d7a101c4919c43d2a018933bd9b898afa5",
      "qualifies": false,
      "readouts": [],
      "span": "In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the strongest Foundayo dose",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "8a6d9908974a592b3cc160d5ccc92a3cdee535b72b5b31ad10e7cd3ff3224fe9",
      "qualifies": false,
      "readouts": [],
      "span": "In late-stage trials, people taking orforglipron lost an average of about 12% of their body weight over roughly 72 weeks.",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "70e050cc87cac72fb6d3c62416994a81c4275c53f9c44202c32d1b6cd69e222d",
      "qualifies": false,
      "readouts": [],
      "span": "| **Foundayo (orforglipron)** | Consumers who strongly prefer a tablet over injections | About 12.4% in cited data[4] | Reported as a newly UAE-approved oral GLP-1 option, but verify Emirates Drug Establishment registration, pharmacy stock,",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "3dd745a455e6747f7f24a1338a047abf4a9a380b64cd483ded9d1f7947c78d96",
      "qualifies": false,
      "readouts": [],
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f76fe3708038aec9b8972e3b38b945a4446e6b240eaabafff259640a2f6991c7",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "9112a4df3478b67e52e67e8f07705f18751a6bb5323297c774ccdb2d54718e3e",
      "qualifies": false,
      "readouts": [],
      "span": "[answer text withheld under the Gemini constraints; engine not recorded]",
      "spanSha256": "7f7348ec291044d2c43d3d9286069cefdd6f6973720efd3794ca2abbcae052a1",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "dd179895be6c0f8fe2dcf0e5d65a4e0c804e84f450cb72d7a754458ebe6d7434",
      "qualifies": false,
      "readouts": [],
      "span": "| **Foundayo (orforglipron)** | People who strongly prefer a tablet over injections | Around 12% average weight loss in reported data | A newer daily oral option reportedly approved and entering the UAE market in 2026; availability, pharmac",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    },
    {
      "sha256": "d1d139b26e5fdb5c143fbfbc42c5322e8a169dadc456c0969800ac6d2d7dd928",
      "qualifies": false,
      "readouts": [],
      "span": "The authority clarified that Retatrutide remains in the clinical trial stage and has not been approved for use or distribution in the UAE.",
      "note": "Wider read (agent named with a figure or trial word): reports pre-congress data only (ATTAIN-1 or oral semaglutide trial figures, regulatory status, or an ORION analysis not in the EASD 2026 programme); no readout-set result."
    }
  ]
}